Publications by authors named "Elena Braychenko"

Claim this Profile
C
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Yann-Alexandre Vano, Letuan Phan, Gwenaelle Gravis, Iphigénie Korakis, Friederike Schlürmann, Elena Braychenko

Int J Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Elena Braychenko

Lancet Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Nicolas Epaillard, Audrey Simonaggio, Reza Elaidi, Fouzia Azzouz, Elena Braychenko

Bull Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
Constance Thibault, Reza Elaidi, Yann-Alexandre Vano, Mouna Rouabah, Elena Braychenko

Bull Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis.
Yvonne van Eijk-Hustings, Astrid van Tubergen, Carina Boström, Elena Braychenko, Beate Buss

Ann Rheum Dis· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis